Care Oncology Providers

If you are a Health Care Provider, please click HERE for more information on the COC Protocol.

Our scientists and doctors developed a combination of medicines to deprive cancer of the nutrients it needs to grow and spread. Clinically demonstrated to more than double life expectancy in our peer reviewed Glioblastoma study.

Care Oncology Cancer Treatment

The Care Oncology Protocol ™ is an adjunct treatment consisting of a combination of four re-purposed medications that had been clinically validated to enhance standard of care and improve outcomes.

Care Oncology Cancer Treatment

Figure 1 Overall survival of patients with glioblastoma multiforme (GBM) receiving the METRICS protocol in addtion to optimal standard of care (SoC) (A) Kaplan-Meier plot of survival in patients with GM receiving the METRICS protocol in addition to SoC, with uncensored patient numbers over time and the percentages of patients receiving the SoCs. The pie chart shows the distribution of SoC treatments. (B) Median overall survival and 2 year survival of patients receiving optimal SoC alongside the off-label medications in the METRICS study cohort compared with other GBM patient cohorts receiving optimal SoC. EORTC, European Organisation for Research and Treatment of Cancer (Stupp et al., 2005). Public Health England (Brodbelt et al., 2015).

Patient Cohort	Median Survival (months)	2 year survival (%)
Care Oncology clinic	27.1	64.0
EORTC	15.8;	26.5
Public Health England	14.8	28.7

Record of Safety

Care Oncology physicians in the United States and the U.K. have safely treated over 2000 patients.

Read Our Study

A New Method for Ethical and Efficient Evidence Generation for Off-Label Medication Use in Oncology.

Read Peer Reviewed Paper

Ongoing Clinical Trial

The Care Oncology treatment is validated by an ongoing clinical trial and a proven record of safety.

How We Partner With Oncologists

Care Oncology partners with oncologists and neuro-oncologists to help patients safely use the COC Protocol metabolic cancer treatment as an adjuvant therapy to standard of care.

Care Oncology Featured in the Economist

Get COC Protocol Information

If you are interested in referring oncology patients, we would love to hear from you.

Provider Form

Record of Safety

Care Oncology physicians in the United States and the U.K. have safely treated over 2000 patients.

Read Our Study

A New Method for Ethical and Efficient Evidence Generation for Off-Label Medication Use in Oncology.

Read Peer Reviewed Paper

Ongoing Clinical Trial

The Care Oncology treatment is validated by an ongoing clinical trial and a proven record of safety.

How We Partner With Oncologists

Care Oncology partners with oncologists and neuro-oncologists to help patients safely use the COC Protocol metabolic cancer treatment as an adjuvant therapy to standard of care.

If you are a Health Care Provider, please click HERE for more information on the COC Protocol.

Care Oncology Cancer Treatment

The Care Oncology Protocol ™ is an adjunct treatment consisting of a combination of four re-purposed medications that had been clinically validated to enhance standard of care and improve outcomes.

Patient Cohort	Median Survival (months)	2 year survival (%)
Care Oncology clinic	27.1	64.0
EORTC	15.8;	26.5
Public Health England	14.8	28.7

Record of Safety

Care Oncology physicians in the United States and the U.K. have safely treated over 2000 patients.

Read Our Study

A New Method for Ethical and Efficient Evidence Generation for Off-Label Medication Use in Oncology.

Read Peer Reviewed Paper

Ongoing Clinical Trial

The Care Oncology treatment is validated by an ongoing clinical trial and a proven record of safety.

How We Partner With Oncologists

Care Oncology partners with oncologists and neuro-oncologists to help patients safely use the COC Protocol metabolic cancer treatment as an adjuvant therapy to standard of care.

Charles J. Meakin, MD, MHA

Medical Director, Care Oncology Clinic USA

Dr. Meakin joined Care Oncology in June 2019 after 30 years of radiation oncology practice in the Charlotte, NC area and Northern California and Cincinnati previously. He has studied health optimization strategies all his career and is a certified Bulletproof Coach and has a charity coaching website called Coach It Forward Chuck. He uses his oncology background with whole patient care strategies to best manage patient goals and foster success. He performed his premedical education at Notre Dame University, Medical School at University of Cincinnati, and Oncology training at Stanford University Hospital. He is also currently in a fellowship studying entrepreneurial strategies at University of Notre Dame ESTEEM Program till 5-2020.

Experience

6/2019-Present
Medical Director of Care Oncology Clinic USA

6/2019- Present
University Notre Dame, ESTEEM Program on Entrepreneurial Studies

1/2019- Present
Coach It Forward Chuck Charity Health and Wellness Coaching Hub and Resource

10/94 – 12/18
Medical Director of Radiation Oncology Center at CaroMont Cancer Center, Gaston, Gastonia, NC

9/91 – 7/94
Private Practice Radiation Oncologist, Santa Rosa, CA

9/91 – 6/94 Concurrent with above
Developed an out-patient cancer center with a seven member Medical Oncology Group at Santa Memorial Hospital. Opened 6/95

8/89-9/91
Radiation Oncologist at The Christ Hospital in Private Practice Cincinnati, Ohio

Paul Zhang, M.D., Ph.D.

Dr. Paul Zhang Paul Zhang, M.D., Ph.D. is the founder of the Institute of Integrative BioOncology (I2B). As a physician-scientist, he is board-certified in medical oncology and internal medicine and board-eligible for medical acupuncture. He has more than 10 years of clinical experience and has specialized in medical treatment of gastroenterological, lung, and prostate cancers. As a member of the Society of Integrative Oncology, he strongly advocates the application of evidence-based comprehensive and integrative approaches to treatment and health restoration.

He was named as one of “America’s Top Physicians” in 2008. Dr. Zhang is a well-known researcher and clinician in the areas of cancer stem cells, novel therapies, and solid tumors. He was among the first to define the growth requirements of cancer stem cells. He described the use of a novel class of drugs that induces cancer differentiation and cell death, histone deactylase (HDAC) inhibitors, and Zolinza (vorinostat) was the first FDA-approved HDAC inhibitor. His recent work focuses on the role of cancer stem cells in the response to novel drug combinations. He is a member of the Society of Integrative Oncology.

Zoraida Mendez, M.D.

Dr. Zoraida Mendez Languages: Fluent in Spanish and English

Experience:

October 01, 2002- December 31, 2018 Oncology physician at Salem Regional Medical Center -I was the only oncologist at that facility. Average of twenty five patients per day. Evaluated cases and created the treatments protocols. Did all Oncology inpatient consults.

July,01, 2000 – September 30, 2001 Locum tenems in Oncology for University Hospitals of Cleveland -Part time Emergency Room and Urgent Care physician for University Hospitals of Cleveland.

July,01, 1993- June 30, 2000 Oncology staff physician, Bone marrow transplant Unit Cleveland Clinic Foundation. Cleveland,Ohio.

Education:

July 01, 1990-June 30, 1993. Completed Hematology and Oncology Fellowship program at Cleveland Clinic Foundation, Cleveland,Ohio.

July 01, 1988-June 30, 1990. Hospitalist at Saint Elizabeth Hospital of Youngstown,Ohio.

July 01, 1986-June 30, 1988. Completed Residency in Internal Medicine at Saint Elizabeth Hospital of Youngstown.

July 01, 1985-June 30, 1986. Internship at Saint Elizabeth Hospital of Youngstown.

October 30,1984. Obtained Medical Doctorate degree from Universidad Nacional Pedro Henriquez Urena.

Care Oncology Featured in the Economist

Get COC Protocol Information